The global market for Ophthalmic Drug Delivery System was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Ophthalmic Drug Delivery System, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Ophthalmic Drug Delivery System by region & country, by Type, and by Application.
The Ophthalmic Drug Delivery System market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ophthalmic Drug Delivery System.
麻豆原创 Segmentation
By Company
Aero Pump GmbH
AptarGroup
Bausch Health
Becton Dickinson & Company
EyePoint Pharmaceuticals, Inc.
Gaplast GmbH
Gerresheimer
Nemera
Nipro Corporation
Ocular Therapeutix
Owen Mumford
Silgan Holdings Inc.
Terumo Corporation
West Pharmaceutical Services, Inc.
Kedalion Therapeutics
Re-Vana Therapeutics
Mati Therapeutics, Inc.,
Biocorp Production
Ocumedic, Inc.
Graybug Vision
Taiwan Liposome
Santen Pharmaceutical
Envisia Therapeutics
Clearside Biomedical
Segment by Type:
Implantable Ophthalmic Drug Delivery Systems
Particulate Ophthalmic Drug Delivery Systems
Others
Segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Ophthalmic Drug Delivery System manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Ophthalmic Drug Delivery System in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Ophthalmic Drug Delivery System in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 麻豆原创 Overview
1.1 Ophthalmic Drug Delivery System Product Introduction
1.2 Global Ophthalmic Drug Delivery System 麻豆原创 Size Forecast
1.2.1 Global Ophthalmic Drug Delivery System Sales Value (2019-2030)
1.2.2 Global Ophthalmic Drug Delivery System Sales Volume (2019-2030)
1.2.3 Global Ophthalmic Drug Delivery System Sales Price (2019-2030)
1.3 Ophthalmic Drug Delivery System 麻豆原创 Trends & Drivers
1.3.1 Ophthalmic Drug Delivery System Industry Trends
1.3.2 Ophthalmic Drug Delivery System 麻豆原创 Drivers & Opportunity
1.3.3 Ophthalmic Drug Delivery System 麻豆原创 Challenges
1.3.4 Ophthalmic Drug Delivery System 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Ophthalmic Drug Delivery System Players Revenue Ranking (2023)
2.2 Global Ophthalmic Drug Delivery System Revenue by Company (2019-2024)
2.3 Global Ophthalmic Drug Delivery System Players Sales Volume Ranking (2023)
2.4 Global Ophthalmic Drug Delivery System Sales Volume by Company Players (2019-2024)
2.5 Global Ophthalmic Drug Delivery System Average Price by Company (2019-2024)
2.6 Key Manufacturers Ophthalmic Drug Delivery System Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Ophthalmic Drug Delivery System Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Ophthalmic Drug Delivery System
2.9 Ophthalmic Drug Delivery System 麻豆原创 Competitive Analysis
2.9.1 Ophthalmic Drug Delivery System 麻豆原创 Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Ophthalmic Drug Delivery System Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ophthalmic Drug Delivery System as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Implantable Ophthalmic Drug Delivery Systems
3.1.2 Particulate Ophthalmic Drug Delivery Systems
3.1.3 Others
3.2 Global Ophthalmic Drug Delivery System Sales Value by Type
3.2.1 Global Ophthalmic Drug Delivery System Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Ophthalmic Drug Delivery System Sales Value, by Type (2019-2030)
3.2.3 Global Ophthalmic Drug Delivery System Sales Value, by Type (%) (2019-2030)
3.3 Global Ophthalmic Drug Delivery System Sales Volume by Type
3.3.1 Global Ophthalmic Drug Delivery System Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Ophthalmic Drug Delivery System Sales Volume, by Type (2019-2030)
3.3.3 Global Ophthalmic Drug Delivery System Sales Volume, by Type (%) (2019-2030)
3.4 Global Ophthalmic Drug Delivery System Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Clinics
4.1.3 Ambulatory Surgical Centers
4.1.4 Others
4.2 Global Ophthalmic Drug Delivery System Sales Value by Application
4.2.1 Global Ophthalmic Drug Delivery System Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Ophthalmic Drug Delivery System Sales Value, by Application (2019-2030)
4.2.3 Global Ophthalmic Drug Delivery System Sales Value, by Application (%) (2019-2030)
4.3 Global Ophthalmic Drug Delivery System Sales Volume by Application
4.3.1 Global Ophthalmic Drug Delivery System Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Ophthalmic Drug Delivery System Sales Volume, by Application (2019-2030)
4.3.3 Global Ophthalmic Drug Delivery System Sales Volume, by Application (%) (2019-2030)
4.4 Global Ophthalmic Drug Delivery System Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Ophthalmic Drug Delivery System Sales Value by Region
5.1.1 Global Ophthalmic Drug Delivery System Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Ophthalmic Drug Delivery System Sales Value by Region (2019-2024)
5.1.3 Global Ophthalmic Drug Delivery System Sales Value by Region (2025-2030)
5.1.4 Global Ophthalmic Drug Delivery System Sales Value by Region (%), (2019-2030)
5.2 Global Ophthalmic Drug Delivery System Sales Volume by Region
5.2.1 Global Ophthalmic Drug Delivery System Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Ophthalmic Drug Delivery System Sales Volume by Region (2019-2024)
5.2.3 Global Ophthalmic Drug Delivery System Sales Volume by Region (2025-2030)
5.2.4 Global Ophthalmic Drug Delivery System Sales Volume by Region (%), (2019-2030)
5.3 Global Ophthalmic Drug Delivery System Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Ophthalmic Drug Delivery System Sales Value, 2019-2030
5.4.2 North America Ophthalmic Drug Delivery System Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Ophthalmic Drug Delivery System Sales Value, 2019-2030
5.5.2 Europe Ophthalmic Drug Delivery System Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Ophthalmic Drug Delivery System Sales Value, 2019-2030
5.6.2 Asia Pacific Ophthalmic Drug Delivery System Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Ophthalmic Drug Delivery System Sales Value, 2019-2030
5.7.2 South America Ophthalmic Drug Delivery System Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Ophthalmic Drug Delivery System Sales Value, 2019-2030
5.8.2 Middle East & Africa Ophthalmic Drug Delivery System Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Ophthalmic Drug Delivery System Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Ophthalmic Drug Delivery System Sales Value
6.2.1 Key Countries/Regions Ophthalmic Drug Delivery System Sales Value, 2019-2030
6.2.2 Key Countries/Regions Ophthalmic Drug Delivery System Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Ophthalmic Drug Delivery System Sales Value, 2019-2030
6.3.2 United States Ophthalmic Drug Delivery System Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Ophthalmic Drug Delivery System Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Ophthalmic Drug Delivery System Sales Value, 2019-2030
6.4.2 Europe Ophthalmic Drug Delivery System Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Ophthalmic Drug Delivery System Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Ophthalmic Drug Delivery System Sales Value, 2019-2030
6.5.2 China Ophthalmic Drug Delivery System Sales Value by Type (%), 2023 VS 2030
6.5.3 China Ophthalmic Drug Delivery System Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Ophthalmic Drug Delivery System Sales Value, 2019-2030
6.6.2 Japan Ophthalmic Drug Delivery System Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Ophthalmic Drug Delivery System Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Ophthalmic Drug Delivery System Sales Value, 2019-2030
6.7.2 South Korea Ophthalmic Drug Delivery System Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Ophthalmic Drug Delivery System Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Ophthalmic Drug Delivery System Sales Value, 2019-2030
6.8.2 Southeast Asia Ophthalmic Drug Delivery System Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Ophthalmic Drug Delivery System Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Ophthalmic Drug Delivery System Sales Value, 2019-2030
6.9.2 India Ophthalmic Drug Delivery System Sales Value by Type (%), 2023 VS 2030
6.9.3 India Ophthalmic Drug Delivery System Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Aero Pump GmbH
7.1.1 Aero Pump GmbH Company Information
7.1.2 Aero Pump GmbH Introduction and Business Overview
7.1.3 Aero Pump GmbH Ophthalmic Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Aero Pump GmbH Ophthalmic Drug Delivery System Product Offerings
7.1.5 Aero Pump GmbH Recent Development
7.2 AptarGroup
7.2.1 AptarGroup Company Information
7.2.2 AptarGroup Introduction and Business Overview
7.2.3 AptarGroup Ophthalmic Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
7.2.4 AptarGroup Ophthalmic Drug Delivery System Product Offerings
7.2.5 AptarGroup Recent Development
7.3 Bausch Health
7.3.1 Bausch Health Company Information
7.3.2 Bausch Health Introduction and Business Overview
7.3.3 Bausch Health Ophthalmic Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Bausch Health Ophthalmic Drug Delivery System Product Offerings
7.3.5 Bausch Health Recent Development
7.4 Becton Dickinson & Company
7.4.1 Becton Dickinson & Company Company Information
7.4.2 Becton Dickinson & Company Introduction and Business Overview
7.4.3 Becton Dickinson & Company Ophthalmic Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Becton Dickinson & Company Ophthalmic Drug Delivery System Product Offerings
7.4.5 Becton Dickinson & Company Recent Development
7.5 EyePoint Pharmaceuticals, Inc.
7.5.1 EyePoint Pharmaceuticals, Inc. Company Information
7.5.2 EyePoint Pharmaceuticals, Inc. Introduction and Business Overview
7.5.3 EyePoint Pharmaceuticals, Inc. Ophthalmic Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
7.5.4 EyePoint Pharmaceuticals, Inc. Ophthalmic Drug Delivery System Product Offerings
7.5.5 EyePoint Pharmaceuticals, Inc. Recent Development
7.6 Gaplast GmbH
7.6.1 Gaplast GmbH Company Information
7.6.2 Gaplast GmbH Introduction and Business Overview
7.6.3 Gaplast GmbH Ophthalmic Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Gaplast GmbH Ophthalmic Drug Delivery System Product Offerings
7.6.5 Gaplast GmbH Recent Development
7.7 Gerresheimer
7.7.1 Gerresheimer Company Information
7.7.2 Gerresheimer Introduction and Business Overview
7.7.3 Gerresheimer Ophthalmic Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Gerresheimer Ophthalmic Drug Delivery System Product Offerings
7.7.5 Gerresheimer Recent Development
7.8 Nemera
7.8.1 Nemera Company Information
7.8.2 Nemera Introduction and Business Overview
7.8.3 Nemera Ophthalmic Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Nemera Ophthalmic Drug Delivery System Product Offerings
7.8.5 Nemera Recent Development
7.9 Nipro Corporation
7.9.1 Nipro Corporation Company Information
7.9.2 Nipro Corporation Introduction and Business Overview
7.9.3 Nipro Corporation Ophthalmic Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Nipro Corporation Ophthalmic Drug Delivery System Product Offerings
7.9.5 Nipro Corporation Recent Development
7.10 Ocular Therapeutix
7.10.1 Ocular Therapeutix Company Information
7.10.2 Ocular Therapeutix Introduction and Business Overview
7.10.3 Ocular Therapeutix Ophthalmic Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Ocular Therapeutix Ophthalmic Drug Delivery System Product Offerings
7.10.5 Ocular Therapeutix Recent Development
7.11 Owen Mumford
7.11.1 Owen Mumford Company Information
7.11.2 Owen Mumford Introduction and Business Overview
7.11.3 Owen Mumford Ophthalmic Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Owen Mumford Ophthalmic Drug Delivery System Product Offerings
7.11.5 Owen Mumford Recent Development
7.12 Silgan Holdings Inc.
7.12.1 Silgan Holdings Inc. Company Information
7.12.2 Silgan Holdings Inc. Introduction and Business Overview
7.12.3 Silgan Holdings Inc. Ophthalmic Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Silgan Holdings Inc. Ophthalmic Drug Delivery System Product Offerings
7.12.5 Silgan Holdings Inc. Recent Development
7.13 Terumo Corporation
7.13.1 Terumo Corporation Company Information
7.13.2 Terumo Corporation Introduction and Business Overview
7.13.3 Terumo Corporation Ophthalmic Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Terumo Corporation Ophthalmic Drug Delivery System Product Offerings
7.13.5 Terumo Corporation Recent Development
7.14 West Pharmaceutical Services, Inc.
7.14.1 West Pharmaceutical Services, Inc. Company Information
7.14.2 West Pharmaceutical Services, Inc. Introduction and Business Overview
7.14.3 West Pharmaceutical Services, Inc. Ophthalmic Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
7.14.4 West Pharmaceutical Services, Inc. Ophthalmic Drug Delivery System Product Offerings
7.14.5 West Pharmaceutical Services, Inc. Recent Development
7.15 Kedalion Therapeutics
7.15.1 Kedalion Therapeutics Company Information
7.15.2 Kedalion Therapeutics Introduction and Business Overview
7.15.3 Kedalion Therapeutics Ophthalmic Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
7.15.4 Kedalion Therapeutics Ophthalmic Drug Delivery System Product Offerings
7.15.5 Kedalion Therapeutics Recent Development
7.16 Re-Vana Therapeutics
7.16.1 Re-Vana Therapeutics Company Information
7.16.2 Re-Vana Therapeutics Introduction and Business Overview
7.16.3 Re-Vana Therapeutics Ophthalmic Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
7.16.4 Re-Vana Therapeutics Ophthalmic Drug Delivery System Product Offerings
7.16.5 Re-Vana Therapeutics Recent Development
7.17 Mati Therapeutics, Inc.,
7.17.1 Mati Therapeutics, Inc., Company Information
7.17.2 Mati Therapeutics, Inc., Introduction and Business Overview
7.17.3 Mati Therapeutics, Inc., Ophthalmic Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
7.17.4 Mati Therapeutics, Inc., Ophthalmic Drug Delivery System Product Offerings
7.17.5 Mati Therapeutics, Inc., Recent Development
7.18 Biocorp Production
7.18.1 Biocorp Production Company Information
7.18.2 Biocorp Production Introduction and Business Overview
7.18.3 Biocorp Production Ophthalmic Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
7.18.4 Biocorp Production Ophthalmic Drug Delivery System Product Offerings
7.18.5 Biocorp Production Recent Development
7.19 Ocumedic, Inc.
7.19.1 Ocumedic, Inc. Company Information
7.19.2 Ocumedic, Inc. Introduction and Business Overview
7.19.3 Ocumedic, Inc. Ophthalmic Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
7.19.4 Ocumedic, Inc. Ophthalmic Drug Delivery System Product Offerings
7.19.5 Ocumedic, Inc. Recent Development
7.20 Graybug Vision
7.20.1 Graybug Vision Company Information
7.20.2 Graybug Vision Introduction and Business Overview
7.20.3 Graybug Vision Ophthalmic Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
7.20.4 Graybug Vision Ophthalmic Drug Delivery System Product Offerings
7.20.5 Graybug Vision Recent Development
7.21 Taiwan Liposome
7.21.1 Taiwan Liposome Company Information
7.21.2 Taiwan Liposome Introduction and Business Overview
7.21.3 Taiwan Liposome Ophthalmic Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
7.21.4 Taiwan Liposome Ophthalmic Drug Delivery System Product Offerings
7.21.5 Taiwan Liposome Recent Development
7.22 Santen Pharmaceutical
7.22.1 Santen Pharmaceutical Company Information
7.22.2 Santen Pharmaceutical Introduction and Business Overview
7.22.3 Santen Pharmaceutical Ophthalmic Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
7.22.4 Santen Pharmaceutical Ophthalmic Drug Delivery System Product Offerings
7.22.5 Santen Pharmaceutical Recent Development
7.23 Envisia Therapeutics
7.23.1 Envisia Therapeutics Company Information
7.23.2 Envisia Therapeutics Introduction and Business Overview
7.23.3 Envisia Therapeutics Ophthalmic Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
7.23.4 Envisia Therapeutics Ophthalmic Drug Delivery System Product Offerings
7.23.5 Envisia Therapeutics Recent Development
7.24 Clearside Biomedical
7.24.1 Clearside Biomedical Company Information
7.24.2 Clearside Biomedical Introduction and Business Overview
7.24.3 Clearside Biomedical Ophthalmic Drug Delivery System Sales, Revenue and Gross Margin (2019-2024)
7.24.4 Clearside Biomedical Ophthalmic Drug Delivery System Product Offerings
7.24.5 Clearside Biomedical Recent Development
8 Industry Chain Analysis
8.1 Ophthalmic Drug Delivery System Industrial Chain
8.2 Ophthalmic Drug Delivery System Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Ophthalmic Drug Delivery System Sales Model
8.5.2 Sales Channel
8.5.3 Ophthalmic Drug Delivery System Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Aero Pump GmbH
AptarGroup
Bausch Health
Becton Dickinson & Company
EyePoint Pharmaceuticals, Inc.
Gaplast GmbH
Gerresheimer
Nemera
Nipro Corporation
Ocular Therapeutix
Owen Mumford
Silgan Holdings Inc.
Terumo Corporation
West Pharmaceutical Services, Inc.
Kedalion Therapeutics
Re-Vana Therapeutics
Mati Therapeutics, Inc.,
Biocorp Production
Ocumedic, Inc.
Graybug Vision
Taiwan Liposome
Santen Pharmaceutical
Envisia Therapeutics
Clearside Biomedical
听
听
*If Applicable.
